Estragole, also widely called methyl chavicol, is an anise-sweet phenylpropanoid that appears across basil, tarragon, fennel, anise, and star anise oils in the AromaForge archive. Its identity and occurrence data are strong, but the public literature around human use is dominated by safety and metabolism rather than wellness efficacy. Current source-grounded framing should treat estragole as an important aroma constituent with a well-studied bioactivation pathway and a significant regulatory toxicology discussion, not as a benefit-forward active.
Chemical identity and composition
PubChem identifies estragole as C10H12O and the IUPAC name 1-methoxy-4-prop-2-enylbenzene. EMA classifies it as a volatile phenylpropanoid alkenylbenzene and documents that it can be either a major or minor constituent depending on the plant and chemotype, which matches its broad spread across estragole-rich and low-estragole archive oils.
Aroma and practical use
- Use the recorded anise, sweet, herbal, green, fennel-like, minty, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A human fennel-tea metabolism study detected rapid estragole 1'-hydroxylation, with conjugated 1'-hydroxyestragole peaking in urine after 1.5 hours and becoming undetectable by 10 hours.
The Europe PMC abstract reports fast human metabolism after fennel-tea exposure, low recovery of conjugated 1'-hydroxyestragole, and substantially higher formation of p-allylphenol than the 1'-hydroxy metabolite.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A human enzyme study found CYP1A2 and CYP2A6 to be the most important enzymes for estragole bioactivation at physiologically relevant concentrations.
The abstract attributes much of human liver 1'-hydroxylation potential to CYP1A2 and CYP2A6 and notes that lifestyle or phenotype differences could shift bioactivation likelihood.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Estragole (Amendment 51, 2023) - Category 5A (leave-on skin) maximum acceptable concentration in finished product; basis: dermal sensitization and systemic toxicityEMA states that estragole is a naturally occurring genotoxic carcinogen and recommends keeping intake from herbal medicinal products as low as practically achievable.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
EMA also says exposure should be minimized in sensitive groups such as young children and pregnant or breast-feeding women, and notes that topical risk assessment remains uncertain because dermal absorption data are missing.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Archive copy should avoid translating estragole metabolism or toxicology literature into medical or wellness claims; the strongest constituent-level public evidence is safety-oriented.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
MethyleugenolOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Methyleugenol report →MethyleugenolOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · effect
No source citation attached.
Read Methyleugenol report →How the effects were investigated
cyp_mediated_1_prime_hydroxylation
Human liver enzymes including CYP1A2 and CYP2A6 can convert estragole to 1'-hydroxyestragole, the proximate metabolite discussed in its bioactivation pathway.
This experimental finding does not establish benefit, dose or safety in people using this blend.
reactive_sulfate_conjugate_formation
EMA's public statement describes the consensus safety mechanism as dose-dependent formation of a sulfate conjugate of 1'-hydroxyestragole followed by DNA binding.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- No persuasive constituent-specific human efficacy literature was verified in this pass; the strongest public literature is toxicology and metabolism focused.
- Most archive-relevant occurrence data come from oil composition records rather than standalone estragole clinical or fragrance-use trials.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.